News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Codeego Launches AI-Powered Certified Software Valuation, Creating a New Category for Software Asset Assurance News Codeego Launches AI-Powered Certified Software Valuation, Creating a New Category for Software Asset Assurance News Melodofi President Paul Ogunmefun to Appear as Music & Tech Panelist at The Linq Up BET Awards Weekend in Los Angeles News Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China News PT Merdeka Gold Resources Tbk Debuts on the Main Board of HKEX with a Secondary Listing News Tong Ren Tang Healthcare (02667.HK) Targets Hong Kong IPO
